Aripiprazole for schizophrenia

El-Sayeh, HG; Morganti, Carla

doi:10.1002/14651858.cd004578.pub2

Cited by 21 publications

(10 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that aripiprazole has a relatively low overall liability for EPS (El-Sayeh and Morganti, 2006;Marder et al, 2003). According to the aggregate of available clinical trial data, akathisia, when it does occur, does not seem to interfere with clinical response, occurs early in the course of treatment, is generally mild to moderate in severity, and rarely leads to treatment discontinuation among aripiprazole-treated patients, which is similar to the observations in patients treated with olanzapine and haloperidol.…”

Section: Resultssupporting

confidence: 71%

Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials

et al. 2009

View full text Add to dashboard Cite

The objective of this article is to assess the clinical characteristics of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder receiving aripiprazole, haloperidol, olanzapine, or placebo. We conducted post hoc analyses of pooled safety data from trials in patients with schizophrenia, schizoaffective disorder, and bipolar I disorder. Outcome measures included the incidence of akathisia, time to onset, duration, severity, and discontinuation due to akathisia, concomitant use of benzodiazepines and/or anticholinergics, Barnes Akathisia Rating Scale (BARS) scores, and the correlation between antipsychotic efficacy and akathisia. The results for schizophrenia and schizoaffective disorder were as follows: akathisia in 9% of aripiprazole- and 6% of placebo-treated patients; 12.5% of aripiprazole- versus 24% of haloperidol-treated patients; 11% of aripiprazole- versus 6% of olanzapine-treated patients. Bipolar I disorder: akathisia in 18% of aripiprazole- and 5% of placebo-treated patients. The clinical characteristics of akathisia were similar between each data set, regardless of disease. Akathisia was generally mild-to-moderate in severity. Discontinuation due to akathisia was low in both the schizophrenia trials (aripiprazole 0.3%; placebo 0%; aripiprazole 0.9%; haloperidol 2.3%; aripiprazole 1.2%; olanzapine 0.2%) and the bipolar trials (aripiprazole 2.3%; placebo 0%). Treatment-emergent akathisia was not associated with a poorer clinical response. In conclusion, akathisia with aripiprazole occurred early in treatment, was mild-to-moderate in severity, led to few study discontinuations, and did not compromise therapeutic efficacy.

show abstract

Section: Resultssupporting

confidence: 71%

Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials

et al. 2009

View full text Add to dashboard Cite

show abstract

“…The agent associated with the least risk of daytime somnolence is aripiprazole, which was associated with a 12% incidence of this adverse effect. Quetiapine and ziprasidone were also relatively less likely than the other agents to cause daytime sleepiness, with a 16% rate of reported somnolence Fenton et al, 2000;Gilbody et al, 2000;Thornley et al, 2003;Marques et al, 2004;Srisurapanont et al, 2004;Duggan et al, 2005;El-Sayeh and Morganti, 2006;Jayaram et al, 2006;Joy et al, 2006). The relatively low somnolence rate associated with quetiapine and ziprasidone is notable considering that the studies reviewed in the previous section would suggest that both agents have the capacity to significantly enhance sleep in terms of increasing total sleep time and decreasing awakenings ( Table 2).…”

Section: Daytime Sedationmentioning

confidence: 98%

“…The adverse effect data appearing in Table 3 were compiled from the Cochran reviews of the available controlled trials with each of these agents (Allison et al, 1999;Bagnall et al, 2000;Fenton et al, 2000;Gilbody et al, 2000;Thornley et al, 2003;Marques et al, 2004;Srisurapanont et al, 2004;Duggan et al, 2005;El-Sayeh and Morganti, 2006;Jayaram et al, 2006;Joy et al, 2006). Adverse event reporting is particularly poorly suited in determining the relative degree to which weight gain occurs with therapy.…”

Section: Sleep-wake Function-related Adverse Effectsmentioning

confidence: 99%

See 1 more Smart Citation

Effects of antipsychotic medications on sleep in schizophrenia

Krystal¹,

Goforth²,

Roth

2008

International Clinical Psychopharmacology

View full text Add to dashboard Cite

Schizophrenia is often accompanied by sleep problems. Evidence exists that these sleep difficulties have significant effects on individuals with this disorder. The mainstay of treatment for this condition is the administration of medications that have effects on neurotransmitter systems, which play an important role in sleep-wake function, including histamine, acetylcholine, serotonin, norepinephrine and dopamine. Little systematic attention, however, has been paid to how the sleep effects of these agents might play a role in the course of treatment, function and quality of life of schizophrenia patients. Schizophrenia medications can improve sleep problems and reverse the sleep architectural derangements that are common among patients with schizophrenia and, therefore, have the potential to improve the quality of life and functional capacity of the patient. Conversely, some sleep-wake effects of these medications can impair patient function and quality of life. In this study, we review the effects of schizophrenia medications and discuss their relevance to optimizing the clinical treatment of people with schizophrenia with regard to sleep-wake function.

show abstract

“…The quinolinone derivative APZ shows a unique pharma- cological profile as a potent partial agonist at dopamine and 5-HT1A receptors and as an antagonist at 5-HT2A receptors (Bortolozzi et al 2007;Bowles and Levin 2003;Jordan et al 2004;Shapiro et al 2003). Efficacy and safety in the treatment of schizophrenia have been proven in a variety of clinical trials with different designs (El-Sayeh et al 2006;Kane et al 2002;Sparshatt et al 2010;TranJohnson et al 2007). The partial agonism on dopamine receptors has been proposed as one mechanism to ameliorate the cognitive symptoms of schizophrenia (Kern et al 2006).…”

Section: Introductionmentioning

confidence: 99%